Implantable Stem Cell Encapsulation for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating implanted cells, tissues, and devices are limited by their inability to effectively modulate the biological immune response, leading to suboptimal functionality and fidelity, particularly in conditions such as blood clotting disorders and lysosomal storage diseases.
Innovation Solution
Development of cell compositions comprising engineered mesenchymal stem function cells (MSFCs) that produce therapeutic agents, such as proteins or nucleic acids, which can be encapsulated in implantable elements to modulate the immune response and provide sustained release of therapeutic agents for extended periods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for treating implanted cells are used, then the treatment can be administered, but the biological immune response cannot be effectively modulated, leading to suboptimal functionality and fidelity
Solution Approach 1:
The patent introduces an intermediary substance (polymer coating or encapsulation material) that mediates between the implanted cells and the host immune system. This intermediary layer physically separates the immune system from the therapeutic cells while allowing necessary nutrient and signal exchange, thereby reducing immune rejection and improving cell functionality and fidelity over time
Solution Approach 2:
The patent converts the harmful immune response into a beneficial outcome by engineering the implanted cells to express specific proteins or by using immunomodulatory materials that actively suppress or redirect the immune response. The immune system's natural activity is harnessed to protect the implanted cells rather than destroy them, improving long-term functionality
2Productivity
If implanted cells are used to produce therapeutic agents, then treatment efficacy is improved, but immune response issues arise that limit longevity
Solution Approach 1:
The patent employs flexible polymer shells or thin film encapsulations around implanted cells that selectively permit the passage of small molecules (nutrients, oxygen, therapeutic products) while blocking immune cells and antibodies. This protective barrier maintains high productivity of therapeutic agents while extending the longevity of implanted elements by preventing immune-mediated destruction
Solution Approach 2:
The patent uses composite materials combining biocompatible polymers, immunomodulatory agents, and cell-matrix components to create implantable structures that support sustained therapeutic production. The composite structure integrates multiple functions: structural support, immune protection, nutrient transport, and therapeutic secretion, thereby maintaining productivity while extending longevity
3Reliability
If the immune response is not modulated, then the implantation process is simple, but the functionality and fidelity of implanted cells deteriorate
Solution Approach 1:
The patent merges the immune protection function with the structural support function by integrating immunomodulatory properties directly into the implantable device structure itself. Rather than adding separate immune modulation components, the protective and structural functions are combined in a single integrated system, reducing overall complexity while maintaining high functionality and fidelity
Data Source
AI summary
Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.